Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Current Opinion in Oncology|August 5, 2010
Role of early PET in the management of diffuse large B-cell lymphomaAnne-Sophie Michallet, Judith Trotman, Christelle Tychyj-Pinel
Leukemia & Lymphoma|May 7, 2013
Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphomaJohn F Seymour, Judith Trotman, Michael S Hofman
Internal Medicine Journal|June 16, 2020
Primary objective of Concord Haematology Clinical Research Unit is to contribute independently to quality clinical researchKelvin Truong, Lucia Nigro, Admir Huseincehajic, et al.
Internal Medicine Journal|October 12, 2019
Author replyJudith Trotman, Chan Y Cheah, Paula Marlton, et al.
Hematological Oncology|July 17, 2023
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemiaKarima Amaador, Catherine Thieblemont, Judith Trotman, et al.
Internal Medicine Journal|September 20, 2018
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphomaJudith Trotman, Chan Y Cheah, Paula Marlton, et al.
Internal Medicine Journal|March 1, 2019
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphomaChan Y Cheah, Stephen Opat, Judith Trotman, et al.
Expert Review of Clinical Pharmacology|September 7, 2021
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinibConstantine S Tam, Ying C Ou, Judith Trotman, et al.
Pathology|December 21, 2012
Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvementRobin Gasiorowski, John Gibson, Geoff Watson, et al.
Internal Medicine Journal|March 26, 2019
Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology settingKelvin Truong, Yiu Lam Kwan, Lucia Nigro, et al.
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Current Opinion in Oncology|August 5, 2010
Role of early PET in the management of diffuse large B-cell lymphomaAnne-Sophie Michallet, Judith Trotman, Christelle Tychyj-Pinel
Leukemia & Lymphoma|May 7, 2013
Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphomaJohn F Seymour, Judith Trotman, Michael S Hofman
Internal Medicine Journal|June 16, 2020
Primary objective of Concord Haematology Clinical Research Unit is to contribute independently to quality clinical researchKelvin Truong, Lucia Nigro, Admir Huseincehajic, et al.
Internal Medicine Journal|October 12, 2019
Author replyJudith Trotman, Chan Y Cheah, Paula Marlton, et al.
Hematological Oncology|July 17, 2023
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemiaKarima Amaador, Catherine Thieblemont, Judith Trotman, et al.
Internal Medicine Journal|September 20, 2018
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphomaJudith Trotman, Chan Y Cheah, Paula Marlton, et al.
Internal Medicine Journal|March 1, 2019
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphomaChan Y Cheah, Stephen Opat, Judith Trotman, et al.
Expert Review of Clinical Pharmacology|September 7, 2021
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinibConstantine S Tam, Ying C Ou, Judith Trotman, et al.
Pathology|December 21, 2012
Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvementRobin Gasiorowski, John Gibson, Geoff Watson, et al.
Internal Medicine Journal|March 26, 2019
Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology settingKelvin Truong, Yiu Lam Kwan, Lucia Nigro, et al.
Pageof 15